ScinoPharm Taiwan, Ltd.

TWSE:1789 Rapporto sulle azioni

Cap. di mercato: NT$20.1b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ScinoPharm Taiwan Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Susan Lu

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO3.7yrs
Proprietà del CEOn/a
Durata media del management4.1yrs
Durata media del Consiglio di amministrazione6.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 17
ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

Apr 04
Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Mar 14
A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

Feb 21
Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

Jan 25
ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Jan 04
We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Dec 14
Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

Nov 23
Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

AMMINISTRATORE DELEGATO

Susan Lu

3.7yrs

Mandato

Ms. Li-An Lu, also known as Susan, is Director of SciAnda (Changshu) Pharmaceutical, Ltd. from June 14, 2024. She serves as President and Chief Executive Officer at ScinoPharm Taiwan, Ltd.since 2021. She...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Chih-Hsien Lo
Chairman & General Chief Strategy Officer14.2yrsNessun datoNessun dato
Li-An Lu
President & CEO3.7yrsNessun datoNessun dato
Chih-Hui Lin
Acting Financial Off.14.3yrsNessun datoNessun dato
Ling-Hsiao Lien
Vice-President of Marketing4.1yrsNessun datoNessun dato
Li-Chiao Chang
VP of R&D Division and Chief Scientific Officerno dataNessun dato0%
NT$ 0
Jason Chen
Director of Human Resources & Admin3.3yrsNessun datoNessun dato
Shun Yang Lin
Director of Corporate Developmentno dataNessun datoNessun dato

4.1yrs

Durata media

Gestione esperta: Il team dirigenziale di 1789 è considerato esperto (durata media dell'incarico 4 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Chih-Hsien Lo
Chairman & General Chief Strategy Officer14.2yrsNessun datoNessun dato
Po-Ming Hou
Representative Director7.8yrsNessun datoNessun dato
Fu-Jung Lai
Representative Director5.9yrsNessun datoNessun dato
Shiow-Ling Kao
Representative Director14.2yrsNessun datoNessun dato
Chiou-Ru Shih
Representative Director14.2yrsNessun datoNessun dato
Tsung-Ping Wu
Representative Director9.3yrsNessun datoNessun dato
Jia-Horng Guo
Representative Director7.1yrsNessun datoNessun dato
Li-Tzong Chen
Independent Director6.3yrsNessun datoNessun dato
Ming-Chuan Hsieh
Representative Director6.3yrsNessun datoNessun dato
Ya-Po Yang
Representative Director6.3yrsNessun datoNessun dato
Wen-Chang Chang
Independent Director6.3yrsNessun datoNessun dato
Lewis Lee
Independent Director3.7yrsNessun datoNessun dato

6.7yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1789 sono considerati esperti (durata media dell'incarico 6.6 anni).